Arthur Kunz

1.3k total citations
17 papers, 865 citations indexed

About

Arthur Kunz is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Arthur Kunz has authored 17 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Arthur Kunz's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer therapeutics and mechanisms (4 papers). Arthur Kunz is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer therapeutics and mechanisms (4 papers). Arthur Kunz collaborates with scholars based in United States, United Kingdom and Canada. Arthur Kunz's co-authors include Philip R. Hamann, Nitin K. Damle, John F. DiJoseph, Erwin R. Boghaert, Maureen Dougher, Douglas Armellino, Kiran Khandke, Latha Sridharan, Irwin Hollander and Justin Moran and has published in prestigious journals such as Blood, Analytical Chemistry and Clinical Cancer Research.

In The Last Decade

Arthur Kunz

17 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arthur Kunz United States 13 555 515 237 160 120 17 865
Latha Sridharan United States 10 367 0.7× 230 0.4× 222 0.9× 107 0.7× 64 0.5× 11 656
R N Sridhara United States 5 461 0.8× 272 0.5× 343 1.4× 48 0.3× 109 0.9× 8 974
Arnaud Tiberghien United Kingdom 16 591 1.1× 368 0.7× 364 1.5× 99 0.6× 71 0.6× 25 900
Heather Kostner United States 7 413 0.7× 208 0.4× 263 1.1× 41 0.3× 102 0.8× 12 624
William Hallett United States 11 498 0.9× 230 0.4× 328 1.4× 45 0.3× 513 4.3× 16 1.0k
Daniëlle C.H. Jacobs Netherlands 4 514 0.9× 298 0.6× 366 1.5× 61 0.4× 206 1.7× 9 951
Randall Dere United States 12 529 1.0× 461 0.9× 221 0.9× 134 0.8× 164 1.4× 20 748
Devika Gajria United States 12 536 1.0× 190 0.4× 322 1.4× 52 0.3× 44 0.4× 31 867
SJ Knox United States 12 142 0.3× 387 0.8× 134 0.6× 138 0.9× 111 0.9× 21 586
Sreeni Yalamanchili United States 8 440 0.8× 80 0.2× 266 1.1× 89 0.6× 65 0.5× 17 634

Countries citing papers authored by Arthur Kunz

Since Specialization
Citations

This map shows the geographic impact of Arthur Kunz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Kunz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Kunz more than expected).

Fields of papers citing papers by Arthur Kunz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Kunz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Kunz. The network helps show where Arthur Kunz may publish in the future.

Co-authorship network of co-authors of Arthur Kunz

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur Kunz. A scholar is included among the top collaborators of Arthur Kunz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur Kunz. Arthur Kunz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Kelly, Marcus P., Sosina Makonnen, Carlos Hickey, et al.. (2021). Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts. Molecular Cancer Therapeutics. 20(12_Supplement). P134–P134. 1 indexed citations
2.
Nittoli, Thomas, Frank J. Delfino, Marcus P. Kelly, et al.. (2020). Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids. Bioorganic & Medicinal Chemistry. 28(23). 115785–115785. 4 indexed citations
3.
Kelly, Marcus P., Carlos Hickey, Sosina Makonnen, et al.. (2017). Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers. Molecular Cancer Therapeutics. 16(7). 1299–1311. 19 indexed citations
4.
Andreev, Julian, Andrés E. Perez Bay, Frank J. Delfino, et al.. (2017). Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. Molecular Cancer Therapeutics. 16(4). 681–693. 129 indexed citations
5.
Hollander, Irwin, Arthur Kunz, & Philip R. Hamann. (2007). Selection of Reaction Additives Used in the Preparation of Monomeric Antibody−Calicheamicin Conjugates. Bioconjugate Chemistry. 19(1). 358–361. 56 indexed citations
6.
Boghaert, Erwin R., Kiran Khandke, Latha Sridharan, et al.. (2007). Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples. Cancer Chemotherapy and Pharmacology. 61(6). 1027–1035. 49 indexed citations
7.
DiJoseph, John F., Maureen Dougher, Douglas Armellino, et al.. (2006). CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunology Immunotherapy. 56(7). 1107–1117. 42 indexed citations
8.
Boghaert, Erwin R., Kiran Khandke, Latha Sridharan, et al.. (2006). Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. International Journal of Oncology. 28(3). 675–84. 35 indexed citations
9.
Dunussi‐Joannopoulos, Kyri, Gerald E. Hancock, Arthur Kunz, et al.. (2005). B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood. 106(7). 2235–2243. 33 indexed citations
10.
DiJoseph, John F., Andrew G. Popplewell, Simon Tickle, et al.. (2004). Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunology Immunotherapy. 54(1). 11–24. 55 indexed citations
11.
Boghaert, Erwin R., Latha Sridharan, Douglas Armellino, et al.. (2004). Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts. Clinical Cancer Research. 10(13). 4538–4549. 51 indexed citations
12.
13.
DiJoseph, John F., Mary E.P. Goad, Maureen Dougher, et al.. (2004). Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma. Clinical Cancer Research. 10(24). 8620–8629. 65 indexed citations
14.
DiJoseph, John F., Douglas Armellino, Erwin R. Boghaert, et al.. (2003). Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 103(5). 1807–1814. 245 indexed citations
15.
16.
Goldenberg, David M., et al.. (1992). Microheterogeneity of a purified IgG1, due to asymmetric fab glycosylation. Molecular Immunology. 29(6). 751–758. 19 indexed citations
17.
Hansen, Hans J., et al.. (1990). Labeling of anti-tumor antibodies and antibody fragments with Tc-99m. Cancer treatment and research. 51. 233–244. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Latha Sridharan Breakdown of academic impact, for papers by R N Sridhara Breakdown of academic impact, for papers by Arnaud Tiberghien Breakdown of academic impact, for papers by Heather Kostner Breakdown of academic impact, for papers by William Hallett Breakdown of academic impact, for papers by Daniëlle C.H. Jacobs Breakdown of academic impact, for papers by Randall Dere Breakdown of academic impact, for papers by Devika Gajria Breakdown of academic impact, for papers by SJ Knox Breakdown of academic impact, for papers by Sreeni Yalamanchili
Rankless by CCL
2026